{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:38:25Z","timestamp":1792723105574,"version":"4.5.0"},"reference-count":194,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.neurot.2026.e00934","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T20:19:11Z","timestamp":1788466751000},"page":"e00934","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Brain metastasis: Opportunities for novel therapies"],"prefix":"10.1016","volume":"23","author":[{"given":"Zouina","family":"Sarfraz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupesh","family":"Kotecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Maharaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manmeet S.","family":"Ahluwalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.neurot.2026.e00934_bib203","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/neuonc\/noac118","article-title":"Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions","volume":"24","author":"Aizer","year":"2022","journal-title":"Neuro Oncol"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00934_bib2","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1634\/theoncologist.12-7-766","article-title":"Central nervous system metastases in HER-2\u2013positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors","volume":"12","author":"Gori","year":"2007","journal-title":"Oncologist"},{"issue":"14","key":"10.1016\/j.neurot.2026.e00934_bib184","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1158\/1078-0432.CCR-10-2962","article-title":"Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER","volume":"17","author":"Brufsky","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00934_bib3","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41571-023-00808-4","article-title":"Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer","volume":"20","author":"Pan","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00934_bib4","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1158\/0008-5472.CAN-19-0458","article-title":"Defining the hallmarks of metastasis","volume":"79","author":"Welch","year":"2019","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00934_bib5","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nm.2072","article-title":"Real-time imaging reveals the single steps of brain metastasis formation","volume":"16","author":"Kienast","year":"2010","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00934_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005857","article-title":"The vascular basement membrane as \u201csoil\u201d in brain metastasis","volume":"4","author":"Carbonell","year":"2009","journal-title":"PLoS One"},{"issue":"5422","key":"10.1016\/j.neurot.2026.e00934_bib7","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1126\/science.284.5422.1994","article-title":"Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF","volume":"284","author":"Holash","year":"1999","journal-title":"Science"},{"issue":"18","key":"10.1016\/j.neurot.2026.e00934_bib8","doi-asserted-by":"crossref","first-page":"6222","DOI":"10.1158\/1078-0432.CCR-04-0823","article-title":"Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option","volume":"10","author":"Leenders","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00934_bib9","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nrclinonc.2011.58","article-title":"The biology of brain metastases\u2014translation to new therapies","volume":"8","author":"Eichler","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"issue":"23","key":"10.1016\/j.neurot.2026.e00934_bib10","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1158\/1078-0432.CCR-10-1564","article-title":"Heterogeneous blood\u2013tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer","volume":"16","author":"Lockman","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00934_bib11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood\u2013brain barrier and blood\u2013tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00934_bib12","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s41578-021-00394-w","article-title":"Drug delivery to the central nervous system","volume":"7","author":"Nance","year":"2022","journal-title":"Nat Rev Mater"},{"key":"10.1016\/j.neurot.2026.e00934_bib13","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fonc.2018.00248","article-title":"Unraveling the role of angiogenesis in cancer ecosystems","volume":"8","author":"Zuazo-Gaztelu","year":"2018","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00934_bib14","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.trecan.2018.01.003","article-title":"The evolving landscape of brain metastasis","volume":"4","author":"Valiente","year":"2018","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00934_bib22","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/neuonc\/noae219","article-title":"The immune landscape in brain metastasis","volume":"27","author":"Schreurs","year":"2025","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00934_bib20","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/cac2.12539","article-title":"Immunologic tumor microenvironment modulators for turning cold tumors hot","volume":"44","author":"Khosravi","year":"2024","journal-title":"Cancer Commun"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00934_bib21","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct Targeted Ther"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00934_bib23","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","article-title":"Oligometastases revisited","volume":"8","author":"Weichselbaum","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00934_bib24","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41571-022-00655-9","article-title":"The oligometastatic spectrum in the era of improved detection and modern systemic therapy","volume":"19","author":"Katipally","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00934_bib25","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s11060-016-2208-8","article-title":"A cure is possible: a study of 10-year survivors of brain metastases","volume":"129","author":"Kotecha","year":"2016","journal-title":"Journal of neuro-oncology"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00934_bib26","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13014-024-02542-2","article-title":"Influence of brain metastases on the classification, treatment, and outcome of patients with extracranial oligometastasis: a single-center cross-sectional analysis","volume":"19","author":"Christ","year":"2024","journal-title":"Radiat Oncol"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00934_bib194","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2015-02-626788","article-title":"Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study","volume":"126","author":"Donato","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00934_bib27","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1158\/1078-0432.CCR-06-2659","article-title":"The biology of metastasis to a sanctuary site","volume":"13","author":"Palmieri","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00934_bib28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.10117","article-title":"Intracranial and extracranial progression and their correlation with overall survival after stereotactic radiosurgery in a multi-institutional cohort with brain metastases","volume":"6","author":"Carpenter","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00934_bib29","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/neuonc\/noaa025","article-title":"Estrogen\/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival","volume":"22","author":"Sperduto","year":"2020","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00934_bib30","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.molmed.2024.09.008","article-title":"Molecular evolution of central nervous system metastasis and therapeutic implications","volume":"31","author":"Gritsch","year":"2025","journal-title":"Trends Mol Med"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00934_bib31","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-481114","article-title":"Liquid biopsy approaches for cancer characterization, residual disease detection, and therapy monitoring","volume":"45","author":"Aredo","year":"2025","journal-title":"American Society of Clinical Oncology Educational Book"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00934_bib32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2217\/cns.15.45","article-title":"Does graded Prognostic assessment outperform recursive partitioning analysis in patients with moderate prognosis brain metastases?","volume":"5","author":"Estabrook","year":"2016","journal-title":"CNS Oncol"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00934_bib33","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.2011.38.0527","article-title":"Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases","volume":"30","author":"Sperduto","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00934_bib34","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jamaoncol.2016.3834","article-title":"Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA)","volume":"3","author":"Sperduto","year":"2017","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00934_bib35","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijrobp.2022.03.020","volume":"114","author":"Sperduto","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00934_bib36","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/j.ijrobp.2011.02.027","article-title":"Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases","volume":"82","author":"Sperduto","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00934_bib37","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ijrobp.2020.01.051","article-title":"Beyond an updated graded prognostic assessment (breast GPA): a prognostic index and trends in treatment and survival in breast cancer brain metastases from 1985 to today","volume":"107","author":"Sperduto","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"10.1016\/j.neurot.2026.e00934_bib38","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1200\/JCO-24-01351","article-title":"Improved survival and prognostication in melanoma patients with brain metastases: an update of the melanoma graded prognostic assessment","volume":"43","author":"Sperduto","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00934_bib39","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.ijrobp.2017.06.2454","article-title":"Estimating survival in melanoma patients with brain metastases: an update of the graded prognostic assessment for melanoma using molecular markers (Melanoma-molGPA)","volume":"99","author":"Sperduto","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00934_bib40","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ijrobp.2018.04.006","article-title":"Effect of targeted therapies on prognostic factors, patterns of care, and survival in patients with renal cell carcinoma and brain metastases","volume":"101","author":"Sperduto","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00934_bib41","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/neuonc\/noy099","article-title":"Estimating survival for renal cell carcinoma patients with brain metastases: an update of the renal graded prognostic assessment tool","volume":"20","author":"Sperduto","year":"2018","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00934_bib42","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/S1470-2045(17)30693-9","article-title":"Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the response assessment in neuro-oncology brain metastases working group","volume":"19","author":"Camidge","year":"2018","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00934_bib43","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1093\/neuonc\/noae140","article-title":"BMScope: a scoping review to chart the evolving clinical study landscape in brain and leptomeningeal metastasis","volume":"26","author":"Cheng","year":"2024","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e00934_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102807","article-title":"Central nervous system metastases in advanced non-small cell lung cancer: a review of the therapeutic landscape","volume":"130","author":"Weller","year":"2024","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00934_bib45","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00934_bib46","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: proposal from the RANO group","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.neurot.2026.e00934_bib47","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.2018.77.9363","article-title":"CNS efficacy of osimertinib in patients with T790M-positive advanced non\u2013small-cell lung cancer: data from a randomized phase III trial (AURA3)","volume":"36","author":"Wu","year":"2018","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.neurot.2026.e00934_bib48","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"36","author":"Reungwetwattana","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00934_bib49","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/S1470-2045(21)00545-3","article-title":"Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study","volume":"22","author":"Tawbi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00934_bib51","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1158\/2159-8290.CD-15-0369","article-title":"Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets","volume":"5","author":"Brastianos","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.neurot.2026.e00934_bib201","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40364-024-00566-0","article-title":"Oncogenic alterations in advanced NSCLC: a molecular super-highway","volume":"12","author":"Friedlaender","year":"2024","journal-title":"Biomarker Research"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00934_bib55","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","article-title":"Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial","volume":"21","author":"Goldberg","year":"2020","journal-title":"Lancet Oncol"},{"issue":"28","key":"10.1016\/j.neurot.2026.e00934_bib56","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1200\/JCO.22.02561","article-title":"Phase II trial of atezolizumab combined with carboplatin and pemetrexed for patients with advanced nonsquamous non\u2013small-cell lung cancer with untreated brain metastases (Atezo-Brain, GECP17\/05)","volume":"41","author":"Nadal","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neurot.2026.e00934_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103638","article-title":"First-line camrelizumab plus pemetrexed and carboplatin for advanced non-squamous non-small-cell lung cancer with brain metastases (CAP-BRAIN): final results of a multicentre, open-label, single-arm, phase 2 trial in China","volume":"90","author":"Hou","year":"2025","journal-title":"Eclinicalmedicine"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00934_bib58","doi-asserted-by":"crossref","first-page":"269","DOI":"10.21037\/tlcr-23-687","article-title":"Intracranial response pattern, tolerability and biomarkers associated with brain metastases in non-small cell lung cancer treated by tislelizumab plus chemotherapy","volume":"13","author":"Zhao","year":"2024","journal-title":"Transl Lung Cancer Res"},{"issue":"24","key":"10.1016\/j.neurot.2026.e00934_bib59","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00934_bib202","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jtho.2021.09.014","article-title":"IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain","volume":"17","author":"Nogami","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.neurot.2026.e00934_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114296","article-title":"Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial","volume":"211","author":"Reck","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.neurot.2026.e00934_bib61","series-title":"FDA approves osimertinib for first-line treatment of metastatic NSCLC with most common EGFR mutations","year":"2018"},{"issue":"23","key":"10.1016\/j.neurot.2026.e00934_bib62","doi-asserted-by":"crossref","first-page":"6168","DOI":"10.1158\/1078-0432.CCR-20-2081","article-title":"Biomarkers of osimertinib response in patients with refractory, EGFR-T790M\u2013positive non\u2013small cell lung cancer and central nervous system metastases: the APOLLO study","volume":"26","author":"Xing","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00934_bib63","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1016\/j.jtho.2021.07.026","article-title":"A phase II study of osimertinib for radiotherapy-naive central nervous system metastasis from NSCLC: results for the T790M cohort of the OCEAN study (LOGIK1603\/WJOG9116L)","volume":"16","author":"Yamaguchi","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00934_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtocrr.2023.100587","article-title":"A phase 2 single-arm study of osimertinib for radiotherapy-naive central nervous system metastasis NSCLC: results for the first-line cohort of the OCEAN study (LOGIK 1603\/WJOG 9116L)","volume":"4","author":"Wakuda","year":"2023","journal-title":"JTO Clinical and Research Reports"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00934_bib65","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.23.02219","article-title":"CNS efficacy of osimertinib with or without chemotherapy in epidermal growth factor receptor\u2013mutated advanced non\u2013small-cell lung cancer","volume":"42","author":"J\u00e4nne","year":"2024","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.neurot.2026.e00934_bib66","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00934_bib67","doi-asserted-by":"crossref","DOI":"10.1093\/noajnl\/vdab188","article-title":"Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study","volume":"4","author":"Peled","year":"2022","journal-title":"Neuro-oncology advances"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00934_bib68","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1080\/0284186X.2021.1973092","article-title":"Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and-negative non-small cell lung cancer patients: results from a phase II study","volume":"60","author":"Eide","year":"2021","journal-title":"Acta Oncol"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00934_bib69","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1200\/JCO.23.01521","article-title":"Overall survival from the EORTC LCG-1613 APPLE trial of osimertinib versus gefitinib followed by osimertinib in advanced EGFR-mutant non\u2013small-cell lung cancer","volume":"42","author":"Remon","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00934_bib70","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1470-2045(12)70086-4","article-title":"Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial","volume":"13","author":"Yang","year":"2012","journal-title":"Lancet Oncol"},{"issue":"27","key":"10.1016\/j.neurot.2026.e00934_bib71","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00934_bib72","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","volume":"17","author":"Park","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00934_bib73","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jtho.2015.11.014","article-title":"First-line afatinib versus chemotherapy in patients with non\u2013small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases","volume":"11","author":"Schuler","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.neurot.2026.e00934_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1094195","article-title":"CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations","volume":"13","author":"Kang","year":"2023","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00934_bib75","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1016\/j.cllc.2019.02.009","article-title":"Intracranial responses to afatinib at different doses in patients with EGFR-mutated non\u2013small-cell lung carcinoma and brain metastases","volume":"20","author":"Wei","year":"2019","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00934_bib76","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1186\/s12885-018-5110-2","article-title":"Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases","volume":"18","author":"Tan","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.neurot.2026.e00934_bib77","series-title":"FDA. U.S. food and drug administration: afatinib","year":"2018"},{"key":"10.1016\/j.neurot.2026.e00934_bib196","unstructured":"U.S. Food and Drug Administration. Gilotrif (afatinib) tablets, 20 mg, 30 mg, and 40 mg: NDA 201292 approval letter. Silver Spring (MD): U.S. Food and Drug Administration; 2013 Jul 12 [cited 2026 Aug 23]."},{"issue":"5","key":"10.1016\/j.neurot.2026.e00934_bib78","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jtho.2024.12.029","article-title":"Amivantamab plus lazertinib in patients with EGFR-mutant NSCLC after progression on osimertinib and platinum-based chemotherapy: results from CHRYSALIS-2 cohort A","volume":"20","author":"Besse","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00934_bib79","doi-asserted-by":"crossref","first-page":"103505","DOI":"10.1016\/j.jtho.2025.10.012","article-title":"Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases","volume":"21","author":"Chen","year":"2026","journal-title":"J Thorac Oncol"},{"issue":"17","key":"10.1016\/j.neurot.2026.e00934_bib80","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","article-title":"Overall survival with amivantamab\u2013lazertinib in EGFR-mutated advanced NSCLC","volume":"393","author":"Yang","year":"2025","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.neurot.2026.e00934_bib81","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00934_bib82","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.neurot.2026.e00934_bib83","series-title":"FDA approves lazertinib with amivantamab-vmjw for non-small lung cancer","year":"2024"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00934_bib84","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00934_bib85","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.jtho.2023.06.017","article-title":"Genomic alterations and the incidence of brain metastases in advanced and metastatic NSCLC: a systematic review and meta-analysis","volume":"18","author":"Gillespie","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"24","key":"10.1016\/j.neurot.2026.e00934_bib86","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1200\/JCO.2015.63.5888","article-title":"Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non\u2013small-cell lung cancer: results from PROFILE 1014","volume":"34","author":"Solomon","year":"2016","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.neurot.2026.e00934_bib87","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1200\/JCO.2014.59.0539","article-title":"Clinical experience with crizotinib in patients with advanced ALK-rearranged non\u2013small-cell lung cancer and brain metastases","volume":"33","author":"Costa","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00934_bib88","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00934_bib89","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S2213-2600(19)30053-0","article-title":"Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study","volume":"7","author":"Zhou","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00934_bib90","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.cllc.2022.07.008","article-title":"Efficacy and safety of brigatinib compared with crizotinib in Asian vs. non-Asian patients with locally advanced or metastatic alk\u2013inhibitor-naive alk+ non\u2013small cell lung cancer: final results from the phase III ALTA-1L study","volume":"23","author":"Ahn","year":"2022","journal-title":"Clin Lung Cancer"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00934_bib190","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jamaoncol.2021.3523","article-title":"Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial","volume":"7","author":"Horn","year":"2021","journal-title":"JAMA Oncol"},{"issue":"10072","key":"10.1016\/j.neurot.2026.e00934_bib91","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00934_bib92","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","article-title":"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol"},{"issue":"29","key":"10.1016\/j.neurot.2026.e00934_bib94","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non\u2013small cell lung cancer: 5-year outcomes from the phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00934_bib95","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jtho.2022.02.014","article-title":"Lorlatinib for previously treated ALK-positive advanced NSCLC: primary efficacy and safety from a phase 2 study in people's Republic of China","volume":"17","author":"Lu","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00934_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100342","article-title":"Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I\/II study","volume":"7","author":"Lin","year":"2022","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00934_bib97","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1038\/s41467-025-59744-9","article-title":"Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial","volume":"16","author":"Arrieta","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurot.2026.e00934_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108683","article-title":"Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial","author":"Dingemans","year":"2025","journal-title":"Lung Cancer"},{"issue":"10503","key":"10.1016\/j.neurot.2026.e00934_bib99","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(25)00866-9","article-title":"Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial","volume":"406","author":"Barlesi","year":"2025","journal-title":"Lancet"},{"issue":"28","key":"10.1016\/j.neurot.2026.e00934_bib100","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1200\/JCO.23.00046","article-title":"Intracranial efficacy of adagrasib in patients from the KRYSTAL-1 trial with KRASG12C-mutated non\u2013small-cell lung cancer who have untreated CNS metastases","volume":"41","author":"Negrao","year":"2023","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.neurot.2026.e00934_bib101","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1158\/1078-0432.CCR-22-0383","article-title":"Activity of adagrasib (MRTX849) in brain metastases: preclinical models and clinical data from patients with KRASG12C-mutant non\u2013small cell lung cancer","volume":"28","author":"Sabari","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.neurot.2026.e00934_bib102","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1200\/JCO.22.02524","article-title":"Long-term outcomes and molecular correlates of sotorasib efficacy in patients with pretreated KRAS G12C-mutated non\u2013small-cell lung cancer: 2-year analysis of CodeBreaK 100","volume":"41","author":"Dy","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00934_bib103","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.jtho.2024.08.005","article-title":"Efficacy and safety of KRAS G12C inhibitor IBI351 monotherapy in patients with advanced NSCLC: results from a phase 2 pivotal study","volume":"19","author":"Zhou","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.neurot.2026.e00934_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115301","article-title":"Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: the IFCT-2102 lung KG12Ci study","volume":"219","author":"Wislez","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.neurot.2026.e00934_bib105","series-title":"KROCUS: a phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC","author":"Gregorc","year":"2024"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00934_bib106","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1158\/2159-8290.CD-20-0142","article-title":"BI-3406, a potent and selective SOS1\u2013KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition","volume":"11","author":"Hofmann","year":"2021","journal-title":"Cancer Discov"},{"issue":"15","key":"10.1016\/j.neurot.2026.e00934_bib107","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1200\/JCO-24-02076","article-title":"Selpercatinib in RET fusion\u2013positive non\u2013small cell lung cancer: final safety and efficacy, including overall survival, from the LIBRETTO-001 phase I\/II trial","volume":"43","author":"Gautschi","year":"2025","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.neurot.2026.e00934_bib108","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1158\/1078-0432.CCR-21-0800","article-title":"Intracranial efficacy of selpercatinib in RET fusion-positive non\u2013small cell lung cancers on the LIBRETTO-001 trial","volume":"27","author":"Subbiah","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00934_bib109","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of selpercatinib in RET fusion\u2013positive non\u2013small-cell lung cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.neurot.2026.e00934_bib110","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa2309457","article-title":"First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion\u2013positive NSCLC","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2026.e00934_bib111","article-title":"Intracranial activity of selpercatinib in Chinese patients with advanced RET fusion\u2013positive Non\u2013small-cell lung cancer in the phase II LIBRETTO-321 trial","volume":"7","author":"Cheng","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00934_bib191","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","article-title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study","volume":"22","author":"Gainor","year":"2021","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1016\/j.neurot.2026.e00934_bib112","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1200\/JCO-25-00275","article-title":"Taletrectinib in ROS1+ non\u2013small cell lung cancer: TRUST","volume":"43","author":"P\u00e9rol","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00934_bib113","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 fusion\u2013positive non\u2013small-cell lung cancer","volume":"390","author":"Drilon","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00934_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102237","article-title":"Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer\u2014final results of the EUCROSS trial","volume":"9","author":"Michels","year":"2024","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00934_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103642","article-title":"Phase II study of brigatinib in patients with ROS1 fusion-positive non-small-cell lung cancer: the Barossa study","volume":"9","author":"Niho","year":"2024","journal-title":"ESMO Open"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00934_bib116","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1200\/JCO.20.03025","article-title":"Updated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion\u2013positive non\u2013small-cell lung cancer","volume":"39","author":"Dziadziuszko","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00934_bib192","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S1470-2045(19)30655-2","article-title":"Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial","volume":"20","author":"Shaw","year":"2019","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00934_bib193","first-page":"100347","article-title":"A phase 2 study of lorlatinib in patients with ROS1-rearranged lung cancer with brain-only progression on crizotinib","volume":"3","author":"Schneider","year":"2022","journal-title":"JTO Clin Res Rep"},{"issue":"23","key":"10.1016\/j.neurot.2026.e00934_bib117","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1200\/JCO.2016.71.3701","article-title":"Open-label, multicenter, phase II study of ceritinib in patients with non\u2013small-cell lung cancer harboring ROS1 rearrangement","volume":"35","author":"Lim","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neurot.2026.e00934_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107442","article-title":"Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer","volume":"188","author":"Cho","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.neurot.2026.e00934_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101952","article-title":"Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b\/2 trial","volume":"59","author":"Yu","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00934_bib120","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S1470-2045(24)00441-8","article-title":"Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial","volume":"25","author":"Wolf","year":"2024","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00934_bib121","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jamaoncol.2023.1962","article-title":"Tepotinib treatment in patients with MET exon 14\u2013skipping non\u2013small cell lung cancer: long-term follow-up of the VISION phase 2 nonrandomized clinical trial","volume":"9","author":"Mazieres","year":"2023","journal-title":"JAMA Oncol"},{"issue":"Supplement_3","key":"10.1016\/j.neurot.2026.e00934_bib122","doi-asserted-by":"crossref","first-page":"iii5","DOI":"10.1093\/noajnl\/vdab071.021","article-title":"TRLS-03. Intracranial activity of tepotinib in patients with MET exon 14 (MET ex14) skipping NSCLC enrolled in VISION","volume":"3","author":"Bestvina","year":"2021","journal-title":"Neuro-Oncology Advances"},{"issue":"15_suppl","key":"10.1016\/j.neurot.2026.e00934_bib123","doi-asserted-by":"crossref","first-page":"9084","DOI":"10.1200\/JCO.2021.39.15_suppl.9084","article-title":"Intracranial activity of tepotinib in patients (pts) with MET exon 14 (MET ex14) skipping NSCLC enrolled in VISION","volume":"39","author":"Patel","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00934_bib189","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(12)70432-1","article-title":"Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study","volume":"14","author":"Bachelot","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.neurot.2026.e00934_bib125","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejca.2017.07.024","article-title":"The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: a systematic review and pooled analysis","volume":"84","author":"Petrelli","year":"2017","journal-title":"Eur J Cancer"},{"issue":"13","key":"10.1016\/j.neurot.2026.e00934_bib124","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1200\/JCO.18.01511","article-title":"TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2\u2013positive breast cancer and brain metastases","volume":"37","author":"Freedman","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00934_bib126","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jamaoncol.2016.0237","article-title":"Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the NEfERT-T randomized clinical trial","volume":"2","author":"Awada","year":"2016","journal-title":"JAMA Oncol"},{"issue":"27","key":"10.1016\/j.neurot.2026.e00934_bib127","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.20.00147","article-title":"Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with\u2265 2 HER2-directed regimens: phase III NALA trial","volume":"38","author":"Saura","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00934_bib186","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.neurot.2026.e00934_bib188","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1200\/JCO.20.00775","article-title":"Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial","volume":"38","author":"Lin","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00934_bib187","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaoncol.2022.5610","article-title":"Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial","volume":"9","author":"Lin","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.neurot.2026.e00934_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102837","article-title":"Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases (PERMEATE trial): overall survival results from a multicenter, single-arm, two-cohort, phase 2 trial","volume":"76","author":"Yan","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.neurot.2026.e00934_bib129","doi-asserted-by":"crossref","DOI":"10.21037\/tbcr-20-25","article-title":"Pyrotinib plus capecitabine for human epidermal factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study","volume":"1","author":"Yan","year":"2020","journal-title":"Translational Breast Cancer Research"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00934_bib130","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.annonc.2020.06.020","article-title":"Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial","volume":"31","author":"Montemurro","year":"2020","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00934_bib131","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1158\/2159-8290.CD-22-0837","article-title":"Trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients with brain metastases: a DESTINY-Breast01 subgroup analysis","volume":"12","author":"Jerusalem","year":"2022","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00934_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102924","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial","volume":"9","author":"Hurvitz","year":"2024","journal-title":"ESMO Open"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00934_bib133","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","article-title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00934_bib134","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","article-title":"Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial","volume":"28","author":"Bartsch","year":"2022","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00934_bib135","article-title":"Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial","volume":"9","author":"Batista","year":"2024","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00934_bib195","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/CAD.0000000000001702","article-title":"Efficacy of disitamab vedotin (RC48) for previously treated human epidermal growth factor receptor 2-positive breast cancer with symptomatic brain metastases: a case report and review of the literature","volume":"36","author":"Yang","year":"2025","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.neurot.2026.e00934_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103614","article-title":"Efficacy and safety of ARX788 for individuals with HER2-positive breast cancer and brain metastases (ACE-Breast-06): a single-arm, phase 2 trial in China","volume":"90","author":"Li","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00934_bib138","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.24.00529","article-title":"Trastuzumab duocarmazine in pretreated human epidermal growth factor receptor 2\u2013positive advanced or metastatic breast cancer: an open-label, randomized, phase III trial (TULIP)","volume":"43","author":"Turner","year":"2025","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00934_bib139","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(22)00621-0","article-title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","volume":"23","author":"Meric-Bernstam","year":"2022","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00934_bib140","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S1470-2045(24)00735-6","article-title":"Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study","volume":"26","author":"Long","year":"2025","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00934_bib141","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00934_bib142","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.neurot.2026.e00934_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113531","article-title":"Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial","volume":"199","author":"Di Giacomo","year":"2024","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00934_bib144","doi-asserted-by":"crossref","first-page":"e461","DOI":"10.1016\/S1470-2045(23)00334-0","article-title":"Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study","volume":"24","author":"Dummer","year":"2023","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00934_bib145","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/cncr.34016","article-title":"Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: checkmate 920","volume":"128","author":"Emamekhoo","year":"2022","journal-title":"Cancer"},{"issue":"23","key":"10.1016\/j.neurot.2026.e00934_bib50","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1200\/JCO.18.02218","article-title":"Safety and efficacy of nivolumab in brain metastases from renal cell carcinoma: results of the GETUG-AFU 26 NIVOREN multicenter phase II study","volume":"37","author":"Flippot","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00934_bib146","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003281","article-title":"Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab","volume":"9","author":"Brown","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"10.1016\/j.neurot.2026.e00934_bib147","doi-asserted-by":"crossref","first-page":"116712","DOI":"10.1016\/j.ejca.2026.116712","article-title":"Cabozantinib in patients with non-locally pretreated brain metastases from renal cell carcinoma: Results of the multicenter phase II trial CABRAMET","volume":"239","author":"Negrier","year":"2026","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00934_bib148","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1001\/jamaoncol.2021.4544","article-title":"Clinical activity and safety of cabozantinib for brain metastases in patients with renal cell carcinoma","volume":"7","author":"Hirsch","year":"2021","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00934_bib149","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.clgc.2019.05.002","article-title":"Cabozantinib in renal cell carcinoma with brain metastases: safety and efficacy in a real-world population","volume":"17","author":"Peverelli","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.neurot.2026.e00934_bib150","series-title":"Interim results of prospective pilot phase II trial of concurrent anti-PD-1 and stereotactic radiosurgery (SRS) for melanoma and NSCLC patients with brain metastases (NCT02858869)","author":"Khan","year":"2020"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00934_bib151","doi-asserted-by":"crossref","DOI":"10.1093\/noajnl\/vdad018","article-title":"Phase II multicenter trial combining nivolumab and radiosurgery for NSCLC and RCC brain metastases","volume":"5","author":"Wong","year":"2023","journal-title":"Neuro-Oncology Advances"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00934_bib152","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011432","article-title":"Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase Ib study","volume":"13","author":"Ahmed","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00934_bib153","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijrobp.2017.05.028","article-title":"Phase 1 study of ipilimumab combined with whole brain radiation therapy or radiosurgery for melanoma patients with brain metastases","volume":"99","author":"Williams","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00934_bib154","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006871","article-title":"Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I\/II trial","volume":"11","author":"Altan","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00934_bib155","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.ijrobp.2023.01.017","article-title":"Concurrent administration of immune checkpoint inhibitors and single fraction stereotactic radiosurgery in patients with non-small cell lung cancer, melanoma, and renal cell carcinoma brain metastases","volume":"116","author":"Lehrer","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.neurot.2026.e00934_bib156","doi-asserted-by":"crossref","first-page":"e1399","DOI":"10.1016\/j.wneu.2019.03.110","article-title":"Adverse radiation effect and disease control in patients undergoing stereotactic radiosurgery and immune checkpoint inhibitor therapy for brain metastases","volume":"126","author":"Koenig","year":"2019","journal-title":"World Neurosurg"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00934_bib157","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.ijrobp.2017.11.041","article-title":"Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma","volume":"100","author":"Chen","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00934_bib158","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/neuonc\/noz046","article-title":"The impact of sequencing PD-1\/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis","volume":"21","author":"Kotecha","year":"2019","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00934_bib159","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.ijrobp.2012.11.042","article-title":"A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation therapy oncology group 0320","volume":"85","author":"Sperduto","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00934_bib160","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.3390\/cancers15113015","article-title":"Combination of EGFR-directed tyrosine kinase inhibitors (EGFR-TKI) with radiotherapy in brain metastases from non-small cell lung cancer: a 2010\u20132019 retrospective cohort study","volume":"15","author":"Tatineni","year":"2023","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00934_bib161","doi-asserted-by":"crossref","first-page":"103549","DOI":"10.1016\/j.jtho.2026.01.001","article-title":"Osimertinib and Stereotactic Radiosurgery for Brain Metastases in EGFR-Mutated Lung Cancer: The STARLET Joint Analysis of OUTRUN and LUOSICNS Randomized Trials","volume":"21","author":"Lee","year":"2026","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00934_bib162","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s10143-025-04097-6","article-title":"Radiation therapy combined with tyrosine kinase inhibitors in 826 patients with HER2-positive breast cancer brain metastases: a systematic review and network meta-analysis","volume":"49","author":"Zare","year":"2026","journal-title":"Neurosurg Rev"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00934_bib163","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12885-025-15224-3","article-title":"Tucatinib, trastuzumab, and capecitabine with stereotactic radiosurgery in patients with brain metastases from HER-2 positive breast cancer (TUTOR): Study protocol for a multicenter phase 1 clinical trial","volume":"26","author":"Sarfraz","year":"2025","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00934_bib164","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11060-022-04055-y","article-title":"Trastuzumab emtansine increases the risk of stereotactic radiosurgery-induced radionecrosis in HER2+ breast cancer","volume":"159","author":"Id Said","year":"2022","journal-title":"J Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e00934_bib207","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41523-024-00711-w","article-title":"Multi-institutional report of trastuzumab deruxtecan and stereotactic radiosurgery for HER2 positive and HER2-low breast cancer brain metastases","volume":"10","author":"Khatri","year":"2024","journal-title":"NPJ Breast Cancer"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00934_bib166","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf229","article-title":"Trastuzumab-deruxtecan and radiotherapy: a safety sub-analysis of COMBART prospective cohort study","volume":"30","author":"Ippolito","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.neurot.2026.e00934_bib167","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2026.104691","article-title":"Concomitant radiation therapy and trastuzumab deruxtecan in metastatic breast cancer: feasibility, safety, and outcomes from a real-life multicentre international cohort","author":"Visani","year":"2026","journal-title":"Breast"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00934_bib165","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s11060-025-05230-7","article-title":"Sacituzumab govitecan and stereotactic radiosurgery in the management of HER2 negative breast cancer brain metastases: a multi-institutional report","volume":"175","author":"Khatri","year":"2025","journal-title":"J Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e00934_bib168","series-title":"Risk of radiation necrosis with concurrent antibody-drug conjugates and radiotherapy in HER2-positive breast cancer with brain metastases: a meta-analysis","author":"Sarfraz","year":"2025"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00934_bib169","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-73312-9","article-title":"Consistent opening of the blood brain barrier using focused ultrasound with constant intravenous infusion of microbubble agent","volume":"10","author":"Lapin","year":"2020","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00934_bib170","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jconrel.2012.09.007","article-title":"Ultrasound-mediated blood-brain\/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model","volume":"163","author":"Park","year":"2012","journal-title":"J Contr Release"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00934_bib171","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1158\/0008-5472.CAN-12-2609","article-title":"Focused ultrasound delivers targeted immune cells to metastatic brain tumors","volume":"73","author":"Alkins","year":"2013","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00934_bib172","doi-asserted-by":"crossref","first-page":"8021","DOI":"10.1038\/s41467-024-52329-y","article-title":"Ultrasound frequency-controlled microbubble dynamics in brain vessels regulate the enrichment of inflammatory pathways in the blood-brain barrier","volume":"15","author":"Guo","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurot.2026.e00934_bib173","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jconrel.2016.08.001","article-title":"Growth inhibition in a brain metastasis model by antibody delivery using focused ultrasound-mediated blood-brain barrier disruption","volume":"238","author":"Kobus","year":"2016","journal-title":"J Contr Release"},{"key":"10.1016\/j.neurot.2026.e00934_bib174","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1104594","article-title":"Blood-tumor barrier opening by MRI-guided transcranial focused ultrasound in a preclinical breast cancer brain metastasis model improves efficacy of combinatorial chemotherapy","volume":"13","author":"Arsiwala","year":"2023","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00934_bib175","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/neuonc\/nov318","article-title":"Early treatment of HER2-amplified brain tumors with targeted NK-92 cells and focused ultrasound improves survival","volume":"18","author":"Alkins","year":"2016","journal-title":"Neuro Oncol"},{"issue":"615","key":"10.1016\/j.neurot.2026.e00934_bib176","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj4011","article-title":"MR-guided focused ultrasound enhances delivery of trastuzumab to Her2-positive brain metastases","volume":"13","author":"Meng","year":"2021","journal-title":"Sci Transl Med"},{"issue":"Suppl 2","key":"10.1016\/j.neurot.2026.e00934_bib177","doi-asserted-by":"crossref","first-page":"ii54","DOI":"10.1093\/neuonc\/noad137.173","article-title":"Lipsman N. P07.13.B A randomized study of low-intensity focused ultrasound for blood-brain disruption for brain metastasis from non-small cell lung cancer (limitless)","volume":"25","author":"Ahluwalia","year":"2023","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00934_bib178","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/s41467-024-45818-7","article-title":"Repeated blood\u2013brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I\/II clinical trial","volume":"15","author":"Carpentier","year":"2024","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00934_bib179","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.3171\/2024.9.JNS24721","article-title":"Focused ultrasound therapy as a strategy for improving glioma treatment","volume":"142","author":"Young","year":"2025","journal-title":"J Neurosurg"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00934_bib180","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41598-018-36340-0","article-title":"Blood-brain barrier opening in primary brain tumors with non-invasive MR-guided focused ultrasound: a clinical safety and feasibility study","volume":"9","author":"Mainprize","year":"2019","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00934_bib181","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijrobp.2025.08.066","article-title":"Tumor Treating Fields Therapy After Stereotactic Radiosurgery for Brain Metastases From Non-Small Cell Lung Cancer: Final Results of the Phase 3 METIS Study","volume":"124","author":"Mehta","year":"2026","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00934_bib182","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.ijrobp.2025.08.027","article-title":"Tumor treating fields (TTFields) after stereotactic radiosurgery (SRS) for brain metastases from non-small cell lung cancer (NSCLC BM): final results of the phase 3 METIS trial","volume":"123","author":"Gondi","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.neurot.2026.e00934_bib199","unstructured":"ClinicalTrials.gov. Radiosurgery Plus NovoTTF-200A for Metastatic Small Cell Lung Cancer to the Brain (RAD 1704). ClinicalTrials.gov identifier: NCT03488472. U.S. National Library of Medicine. Updated May 6, 2023. Accessed March 23, 2026."},{"key":"10.1016\/j.neurot.2026.e00934_bib200","unstructured":"ClinicalTrials.gov. Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases. ClinicalTrials.gov identifier: NCT05341349. U.S. National Library of Medicine. Updated April 23, 2026. Accessed May 23, 2026."},{"key":"10.1016\/j.neurot.2026.e00934_bib185","unstructured":"U.S. Food and Drug Administration. OPTUNE (formerly the NovoTTF-100A System): PMA P100034, Supplement S013. Devices@FDA. Silver Spring, MD: U.S. Food and Drug Administration; 2015 [cited 2026 Mar 7]. Available from: https:\/\/www.accessdata.fda.gov\/SCRIPTS\/cdrh\/devicesatfda\/index.cfm?db=pma&id=352788"},{"key":"10.1016\/j.neurot.2026.e00934_bib205","unstructured":"U.S. Food and Drug Administration. Optune Lua (NovoTTF-100L System): HDE H180002. Silver Spring, MD: U.S. Food and Drug Administration; 2019 May 23 [cited 2026 March 23]."},{"key":"10.1016\/j.neurot.2026.e00934_bib206","unstructured":"U.S. Food and Drug Administration. Optune Lua: PMA P230042. Silver Spring, MD: U.S. Food and Drug Administration; 2024 Oct 15 [cited 2026 March 23]."},{"issue":"5","key":"10.1016\/j.neurot.2026.e00934_bib204","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","article-title":"Bispecific antibody drug conjugates: Making 1+1>2","volume":"14","author":"Gu","year":"2024","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00934_bib197","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neuron.2013.10.061","article-title":"Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle","volume":"81","author":"Niewoehner","year":"2014","journal-title":"Neuron"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926001042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926001042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:55:42Z","timestamp":1792720542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926001042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":194,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1878747926001042"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00934","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brain metastasis: Opportunities for novel therapies","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00934","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00934"}}